Oncotarget

Clinical Research Papers:

Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

Ning Tang, Jun Guo, Qianqian Zhang, Yali Wang and Zhehai Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:3635-3644. https://doi.org/10.18632/oncotarget.6184

Metrics: PDF 2172 views  |   HTML 1169 views  |   ?  


Abstract

Ning Tang1, Jun Guo2, Qianqian Zhang1, Yali Wang2, Zhehai Wang2

1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China

2Department of Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Correspondence to:

Zhehai Wang, e-mail: 731060946@qq.com

Keywords: non-small cell lung cancer, brain metastases, chemotherapy, tyrosine kinase inhibitors, epidermal growth factor receptor

Received: August 11, 2015     Accepted: October 14, 2015     Published: October 20, 2015

ABSTRACT

Control of non-small-cell lung cancer (NSCLC) with brain metastasis is clinically challenging. This study retrospectively evaluated the efficacy of different adjuvant therapies for 776 cases of advanced NSCLCs with brain metastasis who treated with chemotherapy, chemotherapy plus bevacizumab, tyrosine kinase inhibitor (TKI) alone, or supportive care. The median progression-free survival (mPFS) and median overall survival (mOS) of patients treated with chemotherapy plus bevacizumab were 8.5 and 10.5 months, respectively, which were better than those of patients treated with other three therapies(P < 0.01). For patients with EGFR-mutated NSCLC, the efficacy of TKI treatment was not statistically better than that of chemotherapy plus bevacizumab but was significantly better than that of other therapies. Moreover, for patients with EGFR wild-type NSCLC, the mPFS and mOS after chemotherapy plus bevacizumab were greater than those with other two therapies (P < 0.01). The local response rate (RR)and disease control rate (DCR)with regimen including pemetrexed were greater than those with regimen including paclitaxel (P < 0.05). Chemotherapy plus bevacizumab was more effective for NSCLC patients with brain metastasis. Further studies will investigate the benefit of TKI alone for patients with EGFR-mutated. For patients with EGFR wild-type, chemotherapy plus bevacizumab did improve PFS and OS. Furthermore, regimens including pemetrexed led to a greater RR.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6184